UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Fluoxetine versus placebo in posttraumatic stress disorder

The journal of clinical psychiatry, 2002-03, Vol.63 (3), p.199-206

2002

Volltextzugriff (PDF)

Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study

International journal of clinical practice (Esher), 2010-05, Vol.64 (6), p.697-706

2010

Volltextzugriff (PDF)

Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile

European neuropsychopharmacology, 2001-06, Vol.11 (3), p.227-232

2001

Volltextzugriff (PDF)

mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial

Neuroscience and behavioral physiology, 2011-07, Vol.41 (6), p.559-566

2011

Volltextzugriff (PDF)

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

British journal of psychiatry, 2002-10, Vol.181 (4), p.315-320

2002

Volltextzugriff (PDF)

The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2010, Vol.110 (7), p.16

2010

Volltextzugriff (PDF)

Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study

Journal of clinical psychopharmacology, 2007-04, Vol.27 (2), p.166-170

2007

Volltextzugriff (PDF)

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A Pharmacodynamic Responses in Mice, Dogs, and Humans

The Journal of neuroscience, 2015-01, Vol.35 (3)

2015

Volltextzugriff (PDF)

P.3.027 Fluoxetine in the treatment of combat relatedPTSD: A subanalysis of a placebo-controlled trial of Bosnian, Croatian and Serbian veterans of the war in the former Yugoslavia (1992–1995)

European neuropsychopharmacology, 2004-10, Vol.14, p.S315-S315

2004

Volltextzugriff (PDF)

P.7.c.003 Atomoxetine in the treatment of psychostimulant-naive children and adolescents with ADHD: a 6-week, randomized, placebo-controlled trial in Russia

European neuropsychopharmacology, 2006, Vol.16, p.S527-S528

2006

Volltextzugriff (PDF)

Robust Central Reduction of Amyloid- in Humans with an Orally Available, Non-Peptidic -Secretase Inhibitor

The Journal of neuroscience, 2011-11, Vol.31 (46)

2011

Volltextzugriff (PDF)

An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms

The journal of clinical psychiatry, 2001, Vol.62 Suppl 2, p.25

2001

Volltextzugriff (PDF)

Clonazepam for the treatment of stupor in catatonic schizophrenia

The American journal of psychiatry, 1989-09, Vol.146 (9), p.1230a-1230

1989

Volltextzugriff (PDF)

Mood effect of raloxifene in postmenopausal women

Maturitas, 2002-05, Vol.42 (1), p.71-75

2002

Volltextzugriff (PDF)

P.1.191 No clinically significant weight changes associated with long-term oxcarbazepine treatment

European neuropsychopharmacology, 2003-10, Vol.13, p.S256-S256

2003

Volltextzugriff (PDF)

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

British journal of psychiatry, 2002-10 (181), p.315-320

2002

Volltextzugriff (PDF)

Olanzapine versus chlorpromazine in Turkey

Schizophrenia research, 2000, Vol.41 (1), p.190-190

2000

Volltextzugriff (PDF)

Fluoxetine versus placebo in posttraumatic stress disorder

European neuropsychopharmacology, 2001, Vol.11, p.S193-S194

2001

Volltextzugriff (PDF)

On the clinical experience and pharmacology of presynaptic dopamine receptor agonists

European neuropsychopharmacology, 1992-09, Vol.2 (3), p.345-345

1992

Volltextzugriff (PDF)

Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine

European neuropsychopharmacology, 2001, Vol.11, p.S369-S369

2001

Volltextzugriff (PDF)

Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia

European neuropsychopharmacology, 1999-09, Vol.9, p.288-288

1999

Volltextzugriff (PDF)

Fluoxetine in patients with combat-related posttraumatic stress disorder

European neuropsychopharmacology, 2001, Vol.11, p.S300-S301

2001

Volltextzugriff (PDF)

Predictive value of early antianxiety effect on the acute-antipsychotic outcome: A comparison of fluphenazine and olanzapine

Schizophrenia research, 2000, Vol.41 (1), p.191-191

2000

Volltextzugriff (PDF)

Gender differences in the antidepressive effect? A double blind trial of fluoxetine and maprotiline in the treatment of major depression

European neuropsychopharmacology, 2000-09, Vol.10, p.221-221

2000

Volltextzugriff (PDF)

Predictive value of early antianxiety effect on the acute-antipsychotic outcome: a comparison of fluphenazine and olanzapine

European neuropsychopharmacology, 2000-09, Vol.10, p.305-305

2000

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(27)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(10)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Adult
(8)
Female
(8)
Male
(8)
Middle Aged
(8)
Psychiatry
(7)
Double-Blind Method
(5)
Adolescent
(4)
Drug Therapy
(4)
Fluoxetine - Therapeutic Use
(4)
Treatment Outcome
(4)
Adults
(3)
Aged
(3)
Antidepressive Agents, Second-Generation - Adverse Effects
(3)
Antidepressive Agents, Second-Generation - Therapeutic Use
(3)
Antipsychotic Agents - Therapeutic Use
(3)
Biological And Medical Sciences
(3)
Fluoxetine
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Fluoxetine versus placebo in posttraumatic stress disorder

Factors associated with achieving minimally symptomatic status by patients with schizophrenia: results from the 3-year intercontinental schizophrenia outpatients health outcomes study

Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: a double-blind trial of antidepressants with serotonergic or norepinephrinergic reuptake inhibition profile

mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial

Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central A Pharmacodynamic Responses in Mice, Dogs, and Humans

P.3.027 Fluoxetine in the treatment of combat relatedPTSD: A subanalysis of a placebo-controlled trial of Bosnian, Croatian and Serbian veterans of the war in the former Yugoslavia (1992–1995)

P.7.c.003 Atomoxetine in the treatment of psychostimulant-naive children and adolescents with ADHD: a 6-week, randomized, placebo-controlled trial in Russia

Robust Central Reduction of Amyloid- in Humans with an Orally Available, Non-Peptidic -Secretase Inhibitor

An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms

Clonazepam for the treatment of stupor in catatonic schizophrenia

Mood effect of raloxifene in postmenopausal women

P.1.191 No clinically significant weight changes associated with long-term oxcarbazepine treatment

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder

Olanzapine versus chlorpromazine in Turkey

Fluoxetine versus placebo in posttraumatic stress disorder

On the clinical experience and pharmacology of presynaptic dopamine receptor agonists

Sleep quality and early morning wakefulness of schizophrenic patients treated with olanzapine compared to chlorpromazine

Olanzapine versus clozapine in patients non-responsive or intolerant to standard acceptable treatment of schizophrenia

Fluoxetine in patients with combat-related posttraumatic stress disorder

Predictive value of early antianxiety effect on the acute-antipsychotic outcome: A comparison of fluphenazine and olanzapine

Gender differences in the antidepressive effect? A double blind trial of fluoxetine and maprotiline in the treatment of major depression

Predictive value of early antianxiety effect on the acute-antipsychotic outcome: a comparison of fluphenazine and olanzapine

Suchergebnisse filtern